Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study.

Bo Tu, Sulaiman Lakoh, Biao Xu, Marta Lado, Reginald Cole, Fang Chu, Susan Hastings-Spaine, Mohamed Bole Jalloh, Junjie Zheng, Weiwei Chen, Stephen Sevalie
{"title":"Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study.","authors":"Bo Tu,&nbsp;Sulaiman Lakoh,&nbsp;Biao Xu,&nbsp;Marta Lado,&nbsp;Reginald Cole,&nbsp;Fang Chu,&nbsp;Susan Hastings-Spaine,&nbsp;Mohamed Bole Jalloh,&nbsp;Junjie Zheng,&nbsp;Weiwei Chen,&nbsp;Stephen Sevalie","doi":"10.1097/ID9.0000000000000037","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease. There is no recommended antiviral treatment approved for COVID-19 in Sierra Leone, and supportive care and protection of vital organ function are performed for the patients. This study summarized the clinical characteristics, drug treatments, and risk factors for the severity and prognosis of COVID-19 in Sierra Leone to provide evidence for the treatment of COVID-19.</p><p><strong>Methods: </strong>Data of 180 adult COVID-19 patients from the 34th Military Hospital in Freetown Sierra Leone between March 31, 2020 and August 11, 2020 were retrospectively collected. Patients with severe and critically ill are classified in the severe group, while patients that presented asymptomatic, mild, and moderate disease were grouped in the non-severe group. The clinical and laboratory information was retrospectively collected to assess the risk factors and treatment strategies for severe COVID-19. Demographic information, travel history, clinical symptoms and signs, laboratory detection results, chest examination findings, therapeutics, and clinical outcomes were collected from each case file. Multivariate logistic analysis was adopted to identify the risk factors for deaths. Additionally, the clinical efficacy of dexamethasone treatment was investigated.</p><p><strong>Results: </strong>Seventy-six (42.22%) cases were confirmed with severe COVID-19, while 104 patients (57.78%) were divided into the non-severe group. Fever (56.67%, 102/180) and cough (50.00%, 90/180) were the common symptoms of COVID-19. The death rate was 18.89% (34/180), and severe pneumonia (44.12%, 15/34) and septic shock (23.53%, 8/34) represented the leading reasons for deaths. The older age population, a combination of hypertension and diabetes, the presence of pneumonia, and high levels of inflammatory markers were significantly associated with severity of COVID-19 development (<i>P</i> < 0.05 for all). Altered level of consciousness [odds ratio (OR) = 56.574, 95% confidence interval (CI) 5.645-566.940, <i>P</i> = 0.001], high levels of neutrophils (OR = 1.341, 95%CI 1.109-1.621, <i>P</i> = 0.002) and C-reactive protein (CRP) (OR = 1.014, 95%CI 1.003-1.025, <i>P</i> = 0.016) might be indicators for COVID-19 deaths. Dexamethasone treatment could reduce mortality [30.36% (17/56) <i>vs</i>. 50.00% (10/20)] among severe COVID-19 cases, but the results were not statistically significant (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>The development and prognosis of COVID-19 may be significantly correlated with consciousness status, and the levels of neutrophils and CRP.</p>","PeriodicalId":73371,"journal":{"name":"Infectious diseases & immunity","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/fd/id9-2-83.PMC9112504.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases & immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ID9.0000000000000037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: The coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease. There is no recommended antiviral treatment approved for COVID-19 in Sierra Leone, and supportive care and protection of vital organ function are performed for the patients. This study summarized the clinical characteristics, drug treatments, and risk factors for the severity and prognosis of COVID-19 in Sierra Leone to provide evidence for the treatment of COVID-19.

Methods: Data of 180 adult COVID-19 patients from the 34th Military Hospital in Freetown Sierra Leone between March 31, 2020 and August 11, 2020 were retrospectively collected. Patients with severe and critically ill are classified in the severe group, while patients that presented asymptomatic, mild, and moderate disease were grouped in the non-severe group. The clinical and laboratory information was retrospectively collected to assess the risk factors and treatment strategies for severe COVID-19. Demographic information, travel history, clinical symptoms and signs, laboratory detection results, chest examination findings, therapeutics, and clinical outcomes were collected from each case file. Multivariate logistic analysis was adopted to identify the risk factors for deaths. Additionally, the clinical efficacy of dexamethasone treatment was investigated.

Results: Seventy-six (42.22%) cases were confirmed with severe COVID-19, while 104 patients (57.78%) were divided into the non-severe group. Fever (56.67%, 102/180) and cough (50.00%, 90/180) were the common symptoms of COVID-19. The death rate was 18.89% (34/180), and severe pneumonia (44.12%, 15/34) and septic shock (23.53%, 8/34) represented the leading reasons for deaths. The older age population, a combination of hypertension and diabetes, the presence of pneumonia, and high levels of inflammatory markers were significantly associated with severity of COVID-19 development (P < 0.05 for all). Altered level of consciousness [odds ratio (OR) = 56.574, 95% confidence interval (CI) 5.645-566.940, P = 0.001], high levels of neutrophils (OR = 1.341, 95%CI 1.109-1.621, P = 0.002) and C-reactive protein (CRP) (OR = 1.014, 95%CI 1.003-1.025, P = 0.016) might be indicators for COVID-19 deaths. Dexamethasone treatment could reduce mortality [30.36% (17/56) vs. 50.00% (10/20)] among severe COVID-19 cases, but the results were not statistically significant (P > 0.05).

Conclusions: The development and prognosis of COVID-19 may be significantly correlated with consciousness status, and the levels of neutrophils and CRP.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
塞拉利昂成年COVID-19确诊患者严重程度和死亡率的危险因素:一项回顾性研究
背景:新型冠状病毒病2019 (COVID-19)是一种高度传染性呼吸道疾病。塞拉利昂没有批准针对COVID-19的推荐抗病毒治疗,并为患者提供支持性护理和重要器官功能保护。本研究总结了塞拉利昂COVID-19的临床特点、药物治疗、严重程度和预后的危险因素,为COVID-19的治疗提供依据。方法:回顾性收集2020年3月31日至2020年8月11日塞拉利昂弗里敦第34军医院收治的180例成人COVID-19患者资料。重症、危重患者分为重症组,无症状、轻、中度患者分为非重症组。回顾性收集临床和实验室信息,评估重症COVID-19的危险因素和治疗策略。从每个病例档案中收集人口统计信息、旅行史、临床症状和体征、实验室检测结果、胸部检查结果、治疗方法和临床结果。采用多因素logistic分析确定死亡危险因素。并观察地塞米松治疗的临床疗效。结果:确诊重症76例(42.22%),非重症104例(57.78%)。发热(56.67%,102/180)和咳嗽(50.00%,90/180)是新冠肺炎的常见症状。死亡率为18.89%(34/180),其中重症肺炎(44.12%,15/34)和感染性休克(23.53%,8/34)是主要死亡原因。老年人群、高血压和糖尿病的合并、肺炎的存在和高水平的炎症标志物与COVID-19发展的严重程度显著相关(P P = 0.001),高水平的中性粒细胞(OR = 1.341, 95%CI 1.109-1.621, P = 0.002)和c反应蛋白(CRP) (OR = 1.014, 95%CI 1.003-1.025, P = 0.016)可能是COVID-19死亡的指标。地塞米松治疗可降低重症病例死亡率[30.36%(17/56)比50.00%(10/20)],但差异无统计学意义(P > 0.05)。结论:COVID-19的发展和预后可能与意识状态、中性粒细胞和CRP水平显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (Text Extract): Executive Summary. Clinical Epidemiology, Illness Profiles, and the Implication of COVID-19 Before and After the Nationwide Omicron Outbreak During the Winter of 2022 Survey on Changes in the Willingness to Receive the COVID-19 Vaccine Among Patients with Breast Cancer in the Postpandemic Era Immune Profile of COVID-19 Survivors and Contacts During 9 Months: A Cohort Study Effect of Methylprednisolone on Mortality and Clinical Courses in Patients with Severe COVID-19: A Propensity Score Matching Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1